Compare Amgen, Inc. (AMGN) vs Baker Hughes Co (BKR) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amgen, Inc. vs Baker Hughes Co — how do they compare? Amgen, Inc. trades at $363.55 (market cap $196.12B), while Baker Hughes Co trades at $58 (market cap $57.10B). The key difference: Amgen, Inc. is far larger — about 3.4× Baker Hughes Co's market cap, and Amgen, Inc. pays the higher dividend (2.77%). Which is the better fit depends on your goals.
| AMGN | BKR | |
|---|---|---|
Market Cap | $196.12B | $57.10B |
Sector | Health | Energy |
52-Week High | $388.16 | $69.67 |
52-Week Low | $271.18 | $38.68 |
Enterprise Value | $241.41B | $58.50B |
Dividend Yield | 2.77% | 1.6% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMGN trades at $363.39, down slightly by 0.06% today, with a bullish technical signal from moving averages. The company reported strong Q1 2026 earnings, beating estimates with EPS of $5.15 versus $4.77 expected. Revenue grew to $36.75B in 2025, with a net income margin of 20.96%. Recent news includes a favorable court ruling blocking a price cap on Enbrel in Colorado, but regulatory challenges persist for Tavneos in Europe.
The outlook remains positive due to consistent earnings beats and a diversified product portfolio, though risks include regulatory setbacks and competitive pressures. Analyst consensus is bullish with a 57.9% buy rating and a price target of $357.38, slightly below the current price, indicating potential for stability with upside from pipeline developments.
Baker Hughes (BKR) trades at $57.56, up 0.63% with a bearish technical signal despite recent earnings beats. The company shows strong fundamentals with P/E of 18.39, ROE of 17.14%, and consistent revenue growth from $21.2B in 2022 to $27.7B in 2025. Recent contract wins with Cheniere and Kodiak Gas Services highlight expansion in LNG and power infrastructure, supporting long-term growth prospects.
BKR presents a compelling investment case with analyst consensus price target of $73.45 (27% upside) and 66.7% buy ratings. Key opportunities include LNG infrastructure expansion and energy transition projects, while risks involve oil price volatility and execution of the $13.6B Chart Industries acquisition. The stock's current valuation appears reasonable given earnings growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Amgen, Inc.
Amgen is a leader in biotechnology-based human therapeutics, with historical expertise in renal disease and cancer supportive-care products. Flagship drugs include red blood cell boosters Epogen and Aranesp, immune system boosters Neupogen and Neulasta, and Enbrel and Otezla for inflammatory diseases. Amgen introduced its first cancer therapeutic, Vectibix, in 2006 and markets bone-strengthening drug Prolia/Xgeva (approved 2010) and Evenity (2019). The acquisition of Onyx bolstered the firm's therapeutic oncology portfolio with Kyprolis. Recent launches include Repatha (cholesterol-lowering), Aimovig (migraine), Lumakras (lung cancer), and Tezspire (asthma). Amgen's biosimilar portfolio includes Mvasi (biosimilar Avastin), Kanjinti (biosimilar Herceptin), and Amgevita (biosimilar Humira).
Read more on AMGN →About Baker Hughes Co
Baker Hughes is a global leader in oilfield services and oilfield equipment, with particularly strong presences in the artificial lift, specialty chemicals, and completions markets. The other half of its business focuses on industrial power generation, process solutions, and industrial asset management, with high exposure to the liquid natural gas market specifically, as well as broader industrials end markets.
Read more on BKR →
